-+ 0.00%
-+ 0.00%
-+ 0.00%
Biogen’s Diranersen Slows Alzheimer’s Clinical Decline by 38% at Two Years in Phase 2 Study
Share
Listen to the news
Biogen’s Diranersen Slows Alzheimer’s Clinical Decline by 38% at Two Years in Phase 2 Study
  • Biogen announced Phase 2 CELIA results showing diranersen slowed clinical decline in early Alzheimer’s disease, with greater benefit at two years.
  • Results were presented at the 2026 Clinical Trials on Alzheimer’s Disease conference.
  • The 60 mg twice-yearly regimen showed the largest treatment effects; no new safety signals emerged through two years.
  • Two-year findings came from an ongoing open-label extension comparing continued treatment with participants initially assigned to placebo.
  • The findings support further evaluation in a Phase 3 trial; diranersen remains investigational and has no regulatory approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171645OMX_____CNEWS_EN_GNW9879725_en) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending